Sugar-Sweetened and Artificially Sweetened Beverages and Liver Cancer—A Hard Look at Soft Drinks - Scorecard - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Examining the Relationship Between Sugar-Sweetened and Artificially Sweetened Drinks and Liver Cancer Risk

  • By

  • Daniel Clayton-Chubb

  • Andrew T. Chan

  • June 10, 2026

Share

Clinical Scorecard: Examining the Relationship Between Sugar-Sweetened and Artificially Sweetened Drinks and Liver Cancer Risk

At a Glance

CategoryDetail
Condition
Key MechanismsIncreased consumption of sugar-sweetened beverages (SSB) linked to metabolic dysregulation, increased insulin resistance, and hepatic steatosis.
Target Population
Care Setting

Key Highlights

  • SSB consumption associated with increased risk of hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (ICC).
  • 1-beverage/day increase in SSB linked to hazard ratios of 1.10 for HCC and 1.15 for ICC.
  • No association found between artificially sweetened beverages (ASB) and liver cancer.
  • Study utilized data from 11 prospective cohort studies.
  • Observational nature of study limits causality conclusions.

Guideline-Based Recommendations

Diagnosis

  • Monitor liver cancer incidence in populations with high SSB consumption.

Management

  • Encourage reduction of SSB intake.

Monitoring & Follow-up

  • Assess dietary patterns and metabolic health in patients at risk for liver cancer.

Risks

  • Consider potential residual confounding from metabolic disorders.

Patient & Prescribing Data

Individuals with high SSB intake or metabolic disorders.

Clinical Best Practices

  • Advise patients on the risks associated with high SSB consumption.
  • Promote healthy dietary alternatives to SSB.

Related Resources & Content

Original Source(s)

Sugar-Sweetened and Artificially Sweetened Beverages and Liver Cancer—A Hard Look at Soft Drinks

  • by Daniel Clayton-Chubb, Andrew T. Chan

  • June 10, 2026

Related Content

2026 ASCO Breast Cancer Highlights: SENOMAC

Harold Burstein, MD, PhD, and Laura S. Dominici, MD, FACS, discuss highlights from the SENOMAC trial which sheds light on whether some patients with early breast cancer and limited lymph node involvement can safely avoid additional axillary surgery.

  • October 15, 2026

  • 1 min
CRISPR-Based Delivery System Generates CAR T Cells In Vivo

A two-vector delivery system generates tumor-targeting CAR T cells directly inside the body, achieving complete responses in mouse cancer models

  • October 13, 2026

  • 3 min
Bringing CAR T Closer to Home

CAR T Vision aims to widen access to cell therapy by expanding community-based delivery, easing operational barriers, and building sustainable funding models

  • October 13, 2026

  • 8 min